What Is Autosomal Dominant Hypocalcemia With Hypercalciuria?
Autosomal dominant hypocalcemia with hypercalciuria (ADH-HC) is a rare genetic disorder characterized by low blood calcium levels and high calcium excretion in urine, caused by a gain-of-function mutation in the calcium-sensing receptor (CASR) gene, according to a case report published in *Cureus*. This mutation disrupts the body’s ability to regulate calcium homeostasis, leading to symptoms such as muscle cramps, seizures, and kidney stones. The condition is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene from one parent is sufficient to cause the disorder.
How Is ADH-HC Diagnosed?
Diagnosis of ADH-HC typically involves genetic testing to identify mutations in the *CASR* gene, as well as blood and urine tests to assess calcium levels. A 2023 case study described a pediatric patient presenting with recurrent hypocalcemia and hypercalciuria, prompting genetic analysis that confirmed the presence of a specific *CASR* mutation. According to the National Institutes of Health (NIH), early diagnosis is critical to prevent complications such as renal damage and bone density loss.
What Are the Treatment Options?
Treatment for ADH-HC focuses on managing symptoms and preventing complications. Patients often require calcium and vitamin D supplementation to maintain adequate blood calcium levels, while diuretics like thiazides may be prescribed to reduce urinary calcium excretion. The *Cureus* case report highlighted the importance of individualized care, noting that dosages must be carefully monitored to avoid hypercalcemia. Long-term follow-up with a multidisciplinary team, including endocrinologists and nephrologists, is essential.
Why Does This Case Matter for Pediatric Care?
The pediatric case described in the *Cureus* report underscores the challenges of diagnosing ADH-HC in children, as symptoms can overlap with other metabolic disorders. According to the American Academy of Pediatrics, early recognition of genetic causes like *CASR* mutations allows for targeted interventions. This case also emphasizes the need for genetic counseling for families, as the condition has a 50% chance of being passed to offspring.
What Are the Long-Term Prognoses for Patients?
While ADH-HC is a lifelong condition, most patients can achieve stable calcium levels with appropriate management. A 2022 review in *The Journal of Clinical Endocrinology & Metabolism* noted that prognosis varies based on mutation severity and adherence to treatment. Patients are at increased risk for kidney stones and osteoporosis, necessitating regular monitoring. Ongoing research into gene therapy may offer future treatment options, though current approaches remain focused on symptom management.
FAQ: Key Answers for Patients and Families
Can ADH-HC be cured?
No, there is no cure, but symptoms can be managed with medication and lifestyle adjustments.
Is ADH-HC common?
It is extremely rare, with fewer than 100 cases reported globally.
How does the *CASR* mutation affect the body?
The mutation causes the calcium-sensing receptor to remain constantly active, lowering blood calcium and increasing urinary calcium.
Summary and Next Steps
Autosomal dominant hypocalcemia with hypercalciuria is a rare genetic disorder requiring careful diagnosis and management. The case report highlights the importance of genetic testing and personalized treatment plans. For patients and families, understanding the condition and accessing specialized care are critical steps in improving quality of life. Ongoing research may soon provide new therapeutic avenues for this complex condition.